In advanced ovarian cancer tumors, while aromatase activity and ERβ mRNA expression do not correlate with any clinical outcomes [41,42], a recent meta-analysis revealed ERα protein expression was associated with improved OS [43]. This evidence concerns the gene ESR1 and ovarian cancer.